GE and Roche partner to develop integrated digital diagnostics platform

Link-up will improve oncology and critical care treatment

  • Companies aim to develop jointly-branded clinical decision support software for faster, more-accurate, more confident decision-making, enabling earlier diagnosis and individualised treatment
  • Partnership will apply advanced analytics to in-vivo data from GE’s medical imaging and monitoring equipment with in-vitro data from Roche’s biomarker, tissue pathology, genomics and sequencing portfolio

GE Healthcare has entered into a strategic, long-term partnership with Roche to jointly develop and co-market digital clinical decision support solutions.

The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients.

The two companies aim to develop an industry-first digital platform using advanced analytics to provide workflow solutions and apps that support clinical decisions.

This will allow the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real-time monitoring and the latest research outcomes.

Clinicians will then have the comprehensive decision support for providing the right treatment and quality of care for their patients.

We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry

For example, oncology care teams with multiple specialists will have a comprehensive data dashboard to review, collaborate and align on treatment decisions for cancer patients at each stage of their disease.

In the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, tissue pathology, genomic and sequencing data, helping physicians to identify, or even predict severe complications before they strike.

GE Healthcare is a worldwide leader in medical imaging equipment, while Roche Diagnostics is the global leader in in-vitro diagnostics.

“This is the first time that two major players in healthcare have combined advanced analytics with in-vivo and in-vitro diagnostics to this degree”, said Kieran Murphy, president and chief executive of GE Healthcare.

“We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry.”

Roland Diggelmann, chief executive of Roche Diagnostics, added: “This unique partnership will deliver innovative solutions and insights in clinical decision-making.

“Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings.”

Companies